Search

Displaying results 2841 - 2850 of 7186 in total
  1. Drug

    Reserpine

    go.drugbank.com/drugs/DB00206
    ApprovedWithdrawn

    It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. … Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals.

  2. Drug

    Chromic nitrate

    go.drugbank.com/drugs/DB14527
    Approved

  3. Drug

    Nedocromil

    go.drugbank.com/drugs/DB00716
    Approved

    A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.

  4. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. … The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.

  5. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [A247050] The use of oteseconazole is contraindicated in females of reproductive potential due to its embryo-fetal toxicity risks.[L41635] This drug was approved by the FDA on April 26, 2022. … [A247035] This is possible thanks to the tetrazole moiety in oteseconazole that increases target selectivity.

  6. Drug

    Sargramostim

    go.drugbank.com/drugs/DB00020
    ApprovedInvestigational

    Substitution of Leu23 leads to a difference from native protein.

  7. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form.

    Mixtures: RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 14 SAŞE, RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 28 SAŞE
  8. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    It was originally approved by the U.S. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].

  9. Drug

    gamma-Hydroxybutyric acid

    go.drugbank.com/drugs/DB01440
    ApprovedIllicitInvestigational

    It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985).

    Synonyms: oxy-n-butyric acid
  10. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … [L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS<sup>G12C</sup>-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic